Neurocrine (NBIX) CEO Kyle Gano Receives PRSU Award; Shares Withheld

What Happened

• Kyle Gano, CEO of Neurocrine Biosciences (NBIX), had performance restricted stock units (PRSUs) vest on September 11, 2026. The filing shows two grants totaling 8,117 shares (6,275 and 1,842) at $0.00 per share.
• To satisfy tax withholding, the company withheld 4,380 shares (3,386 at $156.22 = $528,961; 994 at $156.22 = $155,283), totaling $684,244 in withholding value. No shares were sold on the open market. Net new shares issued to Gano = 8,117 − 4,380 = 3,737 shares.

Key Details

• Transaction date: September 11, 2026; Form 4 filed September 15, 2026 (timely filing).
• Grants: 6,275 and 1,842 PRSU shares @ $0.00 (vesting triggered by certified performance).
• Withholding (tax payment): 3,386 and 994 shares withheld @ $156.22 (total withheld value $684,244).
• Net increase to insider’s position: +3,737 shares.
• Footnotes: F1 = PRSUs vested after performance was certified; F3 = shares withheld to satisfy tax withholding (no open-market sale); F2 notes inclusion of 176 shares purchased via the 2018 ESPP on Feb 27, 2026.
• Shares owned after the transaction are not provided in the excerpt of the filing.

Context

• This was a vesting of performance RSUs, not a purchase or market sale. The withholding of shares to cover taxes is common and does not indicate an open-market sale.
• For retail investors, awards and subsequent tax-withholdings are routine executive compensation events; they increase insider shareholdings net of withholding but are not direct bullish purchases.